Lenalidomide Sun Pharma

Lenalidomide, the active ingredient in Lenalidomide Sun Pharma, is an immunomodulatory agent presented as an oral dosage form for oral use. It treats multiple myeloma and myelodysplastic syndromes in adult patients.

GNH USA supplies Lenalidomide Sun Pharma as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is employed in hematologic malignancies and related bone‑marrow disorders.

Multiple myeloma: improves progression‑free survival and overall response rates. Myelodysplastic syndromes: reduces transfusion dependence and improves peripheral blood counts.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Neutropenia: reduced neutrophil count. - Thrombocytopenia: lowered platelet levels. - Fatigue: persistent tiredness. - Nausea: upset stomach and vomiting. - Diarrhea: loose stools. - Rash: skin irritation or redness.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in veins. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Secondary primary malignancies: emergence of new cancers. - Hepatic failure: significant liver dysfunction. - Severe infections: opportunistic or bacterial infections.

Before initiating therapy with Lenalidomide, several precautions should be observed. - Monitor blood counts: perform regular CBC to detect neutropenia or thrombocytopenia. - Assess thrombotic risk: evaluate history of clotting disorders and consider prophylactic anticoagulation. - Evaluate renal and hepatic function: adjust use if significant impairment is present. - Avoid use in pregnancy: drug is contraindicated; ensure effective contraception for women of childbearing potential. - Discontinue if severe reactions occur: stop treatment upon signs of serious skin reactions or organ toxicity. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Lenalidomide can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase lenalidomide plasma levels, raising toxicity risk. - Thalidomide: combined use heightens peripheral neuropathy and thrombotic risk. - Anticoagulants (e.g., warfarin): may enhance bleeding tendency.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): reduce lenalidomide exposure, potentially decreasing effectiveness. - NSAIDs: may exacerbate thrombocytopenia and increase bleeding risk.